Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 to 60

Evaluating the effects of RG-RV16 inoculation on airway health

Official title: Epigenetic Mechanism Reprogramming Mucosal Anti-viral Immunity in Allergic Asthma VIRAL MUCOSAL REPROGRAMMING

Run by The University of Texas Medical Branch, Galveston · NCT05331170 · Data updated 2026-11-12

This study is testing whether a new inoculation can improve airway health in people with allergies, asthma, and those without any respiratory issues.

More Asthma trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 60 Years
SexAll
Enrollment75 (estimated)
SponsorThe University of Texas Medical Branch, Galveston
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Galveston, Texas)
StatusRecruiting
StartedApril 27, 2023
Main results expectedMay 1, 2027
Study endsMay 1, 2027
Registry record updatedJanuary 28, 2025
Trial IDNCT05331170 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18-60 with a diagnosis of allergic rhinitis or asthma related to cat dander, as well as healthy individuals without respiratory diseases.

Probably not a fit

Patients with a history of asthma, COPD, or other significant respiratory diseases may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study aims to assess the impact of RG-RV16 inoculation on airway mucosal gene expression and remodeling in three groups: healthy controls, allergic rhinitis subjects with cat dander allergy, and allergic asthmatic subjects. A total of 75 participants will undergo screening, including clinical history, pulmonary function testing, and blood tests to characterize their condition. Only those meeting specific criteria will proceed to the interventional phase, where the effects of the inoculation will be evaluated. The study is designed to provide insights into the mechanisms of airway responses in allergic conditions.

Why it matters

Potential benefit: If successful, this study could lead to new therapeutic strategies for managing asthma and allergic rhinitis.

How similar studies have gone: Other studies have explored similar interventions, but the specific approach of RG-RV16 inoculation in this context is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Healthy Normal Control Group

1. Subject must be able to understand and provide informed consent
2. Age: 18-60 inclusive
3. Sex: M or F
4. No history of asthma, COPD, rhinitis, or other clinically important respiratory disease
5. Non-smoker, or ex-smoker with \<10 pack years, at least 5 years remote.
6. No history of diabetes or cardiovascular disease
7. Negative ImmunoCAP test to regionally relevant allergen panel obtained at Screening. Alternatively, documented history of a negative skin test or negative specific IgE obtained within the past 12 months.

Allergic Rhinitis Group

1. Subject must be able to understand and provide informed consent
2. Age: 18-60 inclusive
3. Sex: M or F
4. No history of asthma, COPD, or other clinically important respiratory disease
5. Non-smoker, or ex-smoker with \<10 pack years, at least 5 years remote
6. No history of diabetes or cardiovascular disease
7. History of rhinitis, physician diagnosed, plus one of the following criteria within the past 12 months
8. Seasonal or perennial nasal congestion or sneezing
9. Seasonal or perennial conjunctival infection or watering
10. No evidence of airway obstruction (FEV1:FVC ≥ lower limit of normal)
11. Positive ImmunoCAP test to cat. Documented history at any time of a positive skin test or a specific IgE measure at least Level 2 reactivity will meet this criterion. Subjects must have cat in home, have regular exposure to cat dander, or live in a home where a cat has lived within the past 6 months.

Allergic Asthma Group

Inclusion Criteria

1. Subject must be able to understand and provide informed consent
2. Age: 18-60 inclusive
3. Sex: M or F
4. No history of COPD or other clinically important respiratory disease other than asthma
5. Non-smoker, or ex-smoker with \<10 pack years, at least 5 years remote
6. No history of diabetes or cardiovascular disease
7. History of mild-moderate asthma, physician diagnosed, plus one of the following criteria within the past 12 months

   1. Airway obstruction (FEV1: FVC \<0.6) that is significantly (at least 12% change from baseline, ATS criteria) reversible after 4 puffs of albuterol (obtained at Screening Visit or documented historical testing performed with the past 12 months)
   2. Requiring ICS for control of asthma for at least 30 days within the past 12 months
8. Positive ImmunoCAP test to cat dander. Documented history at any time of a positive skin test or a specific IgE measure at least Level 2 reactivity will meet this criteria. Subjects must have cat in home, have regular exposure to cat dander, or live in a home where a cat has lived within the past 6 months.
9. Results of the CBC do not show clinically important abnormalities

Exclusion Criteria:

Healthy Group Normal Group

1. Inability or unwillingness of a participant to comply with study protocol
2. Currently taking inhaled corticosteroids, leukotriene modifier, or antihistamines for respiratory disease.
3. Neutralizing Ab to RV16 greater than or equal to 1:8
4. Pregnant or breastfeeding women or a woman who has a planned pregnancy during the course of the study. Menstruating females must have a negative pregnancy test at the screening visit. Pregnancy testing may be conducted prior to procedures as well at various times in the study.
5. Subjects with household or close contacts who are pregnant or planning a pregnancy during the main subject's participation, who have chronic respiratory disease, who are children under the age of 2 years, or who are adults over 60 years of age or are Immunosuppressed e.g. post-chemotherapy, HIV).
6. Subjects who provide healthcare services or work with elderly or children (e.g. daycare provider, senior citizen care giver).

Allergic Rhinitis Group

1. Inability or unwillingness of a participant to comply with study protocol
2. Currently using inhaled steroids, or oral montelukast for respiratory disease
3. Neutralizing Ab to RV16 greater than or equal to 1:8
4. Pregnant or breastfeeding women or a woman who has a planned pregnancy during the course of the study. Menstruating females must have a negative pregnancy test at screening visit. Pregnancy testing may be conducted prior to procedures as well at various times in the study.
5. Subjects with household or close contacts who are pregnant or planning a pregnancy during the main subject's participation, who have chronic respiratory disease, who are children under the age of 2 years, or who are adults over 60 years of age or are Immunosuppressed e.g. post-chemotherapy, HIV) .
6. Subjects who provide healthcare services or work with elderly or children (e.g. daycare provider, senior citizen care giver).
7. Subjects who have received immunosuppressive treatment within the last 12 months
8. BMI is greater than 35
9. History of symptoms consistent with a viral URI within the past 21 days
10. Results of the CBC do not show clinically important abnormalities
11. Family history or medical history of liver disease or bleeding disorders
12. Have not received systemic corticosteroids for 3months prior to Screening
13. Antiplatelet agents other than aspirin
14. Subjects who have a positive COVID-19 test will be excluded for 8 weeks

Allergic Asthma Group

1. Inability or unwillingness of a participant to comply with study protocol
2. Currently taking medications for respiratory diseases other than ICS, montelukast, or rescue albuterol or LABAs.
3. Neutralizing Ab to RV16 greater than or equal to 1:8
4. FEV1: FVC ratio less than 0.6, or FEV1 less than 60% predicted
5. Recent (\<30 days) exacerbation of asthma requiring systemic corticosteroids
6. ICS greater than fluticasone 500 mcg/day or its equivalent (GINA 2019 table) at screening.
7. Pregnant or breastfeeding women or a woman who has a planned pregnancy during the course of the study. Menstruating females must have a negative pregnancy test at screening. Pregnancy testing may be conducted prior to procedures as well at various times in the study.
8. Subjects with household or close contacts who are pregnant or planning a pregnancy during the main subject's participation, who have chronic respiratory disease, who are children under the age of 2 years, or who are adults over 60 years of age or are Immunosuppressed e.g. post-chemotherapy, HIV) .
9. Subjects who provide healthcare services or work with elderly or children (e.g. daycare provider, senior citizen care giver).
10. Subjects who have received immunosuppressive treatment within the last 12 months
11. BMI is greater than 35
12. History of symptoms consistent with a viral URI within the past 21 days
13. Family history or medical history of liver disease or bleeding disorders
14. Have not received systemic corticosteroids for 3 months prior to Screening
15. Have an ACT score \>19 at the time of enrollment.
16. Antiplatelet agents other than aspirin
17. Subjects who have a positive COVID-19 test will be excluded for 8 weeks

Where it's running

  • University of Texas Medical Branch
    Galveston, Texas, United States
    Recruiting

Study contacts

  • Principal investigator: William J. Calhoun, MD — University of Texas
  • Study coordinator: Lisa Sweeney, RN
  • Email: lanemeth@utmb.edu
  • Phone: 409-747-5871

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • EmoTIChealth: a serious game to strengthen emotional skills in teens with and without chronic conditions

    This project will try a digital serious game for 12–16-year-olds to boost socioemotional skills and offer tailored support for teens with asthma, food allergy, type 1 diabetes, or allergic rhinitis.

    Recruiting University of Valencia · Valencia, Valencia · NCT07212530

  • Chronic Respiratory Disease Participant Engagement

    This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.

    Recruiting Richmond Pharmacology Limited · London · NCT07924462

  • Mannan-Conjugated Allergoids for House Dust M mite Allergy

    A new treatment named EP-088_MM09 is being tested to see if it can reduce nasal and eye allergy symptoms (and possibly asthma) in people aged 12 to 65 who are allergic to house dust mites, compared with a placebo.

    Recruiting at 2 sites Phase 3 Inmunotek S.L. · Covilha, Castelo Branco District and 15 other locations · NCT07904195

  • Mannan-conjugated Allergoids for House Dust Mite Allergy

    A new treatment called EP-088_MM09 is being tested to see if it can reduce allergy symptoms in people with house dust mite–related nasal allergy, with or without mild asthma.

    Recruiting at 4 sites Phase 3 Inmunotek S.L. · Coimbra and 15 other locations · NCT07904052

  • HB0056 in adults with moderate to severe asthma

    This study tests HB0056 versus a placebo to see if it helps adults with moderate to severe asthma reduce rescue inhaler use and improve symptoms.

    Recruiting at 2 sites Phase 1/2 Shanghai Huaota Biopharmaceutical Co., Ltd. · Beijing and 1 other locations · NCT07899996

  • Tilrekimig (PF-07275315) for Severe Asthma: Aimed at Adults with Frequent Exacerbations

    This study tests whether tilrekimig helps people with severe asthma who have had multiple flare-ups in the past year, by comparing it to a placebo given every four weeks.

    Recruiting at 4 sites Phase 3 Pfizer · River Forest, Illinois and 11 other locations · NCT07869043

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.